ArticleCureus2025
Indian Interventional Cardiologists' Perspectives on De-escalating Dual to Single Antiplatelet Therapy in High Bleeding Risk (HBR) Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManaging thrombotic and hemorrhagic risks associated with dual antiplatelet therapy (DAPT) in patients with a high bleeding risk (HBR) is challenging, especially in post-percutaneous coronary intervention (PCI) patients. Transitioning from DAPT to single antiplatelet therapy (SAPT) aims to reduce bleeding complications while ensuring sufficient ischemic protection. This study explored Indian interventional cardiologists' views on de-escalation strategies in HBR patients, considering bleeding risk factors, including Indian-specific risks, such as tropical diseases and other comorbidities. MATERIALS AND
methodsA cross-sectional questionnaire-based survey was conducted from June 2024 to July 2024 among 400 interventional cardiologists in India. A structured, pre-validated questionnaire was used to gather data on the perceived prevalence of HBR in routine practice, key HBR factors specific to Indian patients (such as frailty, comorbidities, and tropical diseases), preferred SAPT agents after DAPT, perceived bleeding risk profiles of antiplatelet agents, and barriers to implementation of de-escalation. Participation was voluntary and anonymous. Responses were analyzed using descriptive statistics and reported as frequencies and proportions.
resultsOf the 375 interventional cardiologists, 193 (51.47%) reported an HBR prevalence of less than 10%, and 250 (66.67%) believed that gastrointestinal (GI) bleeding was the most common complication in patients receiving DAPT. The main HBR factors included frailty, reported by 326 (86.90%) cardiologists, chronic kidney disease (CKD) stage 3 or severe, reported by 319 (85.1%) cardiologists, and liver cirrhosis with portal hypertension, reported by 324 (86.4%) interventional cardiologists. After DAPT, 128 (34.13%) cardiologists preferred clopidogrel 75 mg, and 107 (28.53%) preferred aspirin 75 mg. Clopidogrel was seen as the least likely to cause bleeding by 179 (48.00%) interventional cardiologists, with 80 (21.33%) rating it as the best option for HBR patients de-escalating from DAPT to SAPT.
conclusionsThis study presents Indian interventional cardiologists' perspectives on de-escalation strategies, including transitioning from DAPT to SAPT, to reduce bleeding complications, while ensuring adequate ischemic protection in patients with HBR post-PCI. Interventional cardiologists have outlined criteria for identifying critical HBR factors relevant to the Indian population. Clopidogrel was the most preferred medication for transitioning to SAPT in HBR patients. Simplified Indian bleeding risk scoring tools and tailored approaches are essential for improving DAPT management in patients with HBR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.